Vitamin D1

Acts like vitamin D to have calcium absorption from the gut.

Vitamin D2

Like Vitamin D it aids in calcium absorption from the gut.

di-hydroxylate form of vitamin D

Aids in calcium absorption from gut

tri-hydroxylated form of vitamin D

aids in calcium absorption from gut

Type of estrogen

bypasses high first pass metabolism

decrease bone resorption (reduce bone loss and increase bone mass)

Type of estrogen

synthetic modification to increase oral absorption

decreases bone resorption (reduce bone loss and increase bone mass)

type of estrogen

sulfated estrodiol isolated from urine of pregnant mares

reduce bone loss and increase bone mass by decreasing bone resorption

selective estrogen-receptor modifier

This competes with estradiol for estrogen receptor binding

has both estrogenic and anti-estrogenic effects (estrogenic in the bone, anti-estrogenic in the breast)

Can cause nausea and vomiting and hot flashes

Analog of pyrophosphate that inhibit osteoclast formation leading to decreased bone resorption.  prevention and treatment of osteoporosis.

given cyclically for 14 days each month.  Not FDA approved for osteoporosis.

analog of pyrophosphate that inhibit osteoclast formation leading to decreased bone resorption.  this is for the prevention and treatment of osteoporosis.

first on market.  available as daily and weekly PO dosing forms.

Analog of pyrophosphate that inhibit osteoclast formation leading to decreased bone resorption.  prevention and treatment of osteoporosis.

daily and weekly PO dosage forms

Analog of pyrophosphate that inhibit osteoclast formation leading to decreased bone resorption.  prevention and treatment of osteoporosis.

Given by IV every three to six months.  NOt FDA approved for osteoporosis but it is still used.

Analog of pyrophosphate that inhibit osteoclast formation leading to decreased bone resorption.  prevention and treatment of osteoporosis.

PO and IV forms

Peptide hormone (84 amino acids)

Analogous to parathyroid hormone - increased serum calcium and decreased serum phosphate

Increases activity and # of osteoclasts indirectly by acting directly on osteoblasts to produce a protein that acts on osteoclasts (RANKL)

stimulates 1,25-dihydroxyvitamin D production

Very expensive, used for refractory cases of osteoporosis

MOA:  antibody against RANKL.  Therefore, it inhibits the conversion of preosteoclasts to osteoclasts

ADME:  10 day half-life, clinical effects up to 8-9 months, dosed every 6 months SQ

ADRs:  hypocalcemia, increased risk of infection, pancreatitis